Year: 2023

news_6

AnHeart Therapeutics and Innovent Announce China’s NMPA Has Accepted a New Drug Application for Taletrectinib (ROS1 Inhibitor)

NEW YORK & SUZHOU, China--(BUSINESS WIRE)--AnHeart Therapeutics (“AnHeart”), a global clinical-stage biopharmaceutical company developing novel precision therapies for people with...

news_6

China Dongxiang Announces FY2023/24 Interim Results, Distributes Interim Special Dividend of RMB0.71 cents per share, Accumulative Payout Ratio Totalled 72%

Outstanding Offline Sales Performance for Kappa, Apparel Business Achieved Turnaround in Operating Profit Results Highlights Revenue amounted to RMB776 million,...